Skip to main content
OpenTrials
Completed

NCT Number: NCT01460784

STAGES Trial: Study of Adiposity, Growth and Endocrine Stages

The investigators propose to conduct a cross-sectional study of 60 participants who are 18-30 years of age to undergo research PET/CT. The purpose of this study is to investigate the relationships between Brown Adipose Tissue (BAT), the adiponectin/leptin (A/L) ratio, and components of the metabolic syndrome in young adults.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Utah

Salt Lake City, Utah, 84108, United States

About this study

We propose to conduct a cross-sectional study of 60 participants who are 18-30 years of age to undergo research PET/CT. The purpose of this study is to investigate the relationships between Brown Adipose Tissue (BAT), the adiponectin/leptin (A/L) ratio, and components of the metabolic syndrome in young adults. This study is part of a larger study aimed at understanding the mechanism of brown adipose tissue as a potential protective factor against metabolic dysfunction.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females, 18-30 years of age at enrollment, who are obese (BMI greater or equal to 30 kg/m2, weight less than 159 kg) and healthy
  • Without medications and endocrine/genetic disorders known to affect weight.
  • Participants may have insulin resistance, impaired glucose tolerance, dyslipidemia, or hypertension.

Exclusion criteria

  • Anyone who refuses participation.
  • A genetic syndrome or other endocrine disorder known to cause obesity (Prader-Willi, Cushing Syndrome, Leptin deficiency, etc.).
  • Use of the following medications: psychotropics, sulphonylurea, thiazolidinediones, insulin, glucocorticoids, anti-neoplastic agents, angiotensin receptor blocker, angiotensin-converting enzyme inhibitors.
  • Pregnancy or history of pregnancy.
  • Active infectious disease
  • History of CVD or stroke during the previous 36 months
  • Total cholesterol 300 mg/dl, triglycerides 400 mg/dl
  • Blood pressure 140/90 mmHg
  • Fasting plasma glucose 126 mg/dl.
  • Diabetes mellitus, type 1 or 2.

Treatment and study plan

Primary outcomes

  1. Presence of brown adipose tissue

    Time frame: 2 years

Secondary outcomes

  1. Presence of metabolic dysfunction

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Official study title

Changes in Adipokines and Adiposity During Puberty and Young Adulthood

Acronym: STAGES

Important dates

Study start
2010
Primary completion
2015
Study completion
2015
First posted
Oct 27, 2011
Registry last updated
Dec 3, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.